

**INSTRUCTION  
for medical use  
of medicinal product  
LEKSOL®**

***Composition:***

*active ingredients:* benzocaine, bismuth subgallate, zinc oxide, menthol;

1 suppository contains benzocaine (0.1 g) 100 mg, bismuth subgallate (0.04 g) 40 mg, zinc oxide (0.02 g) 20 mg, menthol (0.004 g) 4 mg;

*excipients:* polyethylene oxide 1500, polyethylene oxide 400.

**Dosage form.** Suppositories.

*Main physicochemical properties:* green-yellow, bullet-shaped suppositories.

**Pharmacotherapeutic group.** Agents for treatment of hemorrhoids and anal fissures for topical use. Local anesthetics. ATC code C05A D.

***Pharmacological properties.***

*Pharmacodynamics.*

Leksol® is a complex medicinal product, therapeutic effect of which is due to pharmacological properties of active ingredients in its composition. Leksol® exerts local anesthetic, anti-inflammatory, and astringent effect.

*Pharmacokinetics.*

Has not been studied.

**Clinical particulars.**

***Indications.***

Symptomatic therapy of hemorrhoids and anal fissures.

***Contraindications.***

Hypersensitivity to the drug product ingredients. Hypersensitivity to other amide anesthetic agents.

***Interaction with other medicinal products and other forms of interaction.***

Have not been studied.

***Administration details.***

Monitoring of blood parameters is necessary in the conditions of long-term use.

***Pregnancy and lactation.***

The drug product may be prescribed to pregnant or breastfeeding women by a doctor with consideration of risk/benefit ratio.

***Effects on ability to drive and use machines.***

It is recommended to abstain from driving and performing works requiring increased attention and precise coordination during the period of treatment with this product.

***Posology and method of administration.***

The following should be done before using the suppository:

- tear off one suppository in primary package along the blister package perforation line;
- further, pull the film edges tearing it apart, and release the suppository from primary package.

The drug product is administered by rectal route. 1 suppository 1-2 times daily after an intestinal purgative enema or independent defecation.

The treatment duration is established by a doctor with consideration of the disease course and severity, as well as therapeutic effect achieved.

***Children.*** No data regarding the use of this drug product in children are available.

***Overdose.***

Overdose is unlikely in case the drug product is used in therapeutic doses. Enhancement of adverse reaction manifestations is possible. Therapy is symptomatic.

***Adverse reactions.***

Allergic reactions, skin rash, and itching develop occasionally. The drug product can exert laxative effect and cause itching in anus. Blood disorders (methemoglobinemia) can develop in the conditions of long-term use.

***Shelf life.*** 3 years.

**Storage conditions.** Store at temperature not exceeding 25 °C. Keep away from children.

**Package.** 5 suppositories in a blister, 1 or 2 blisters in a pack.

**Dispensing category.** Over-the-counter drug.

**Manufacturer.** Joint Stock Company «Lekhim-Kharkiv».

**Manufacturer's location and place of business.**

Ukraine, 61115, Kharkiv region, Kharkiv, Severyna Pototskoho street, building 36.

**Date of the last revision.**